1. Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population. (20th May 2020) Authors: Augustin, M.; Dauden, E.; Mrowietz, U.; Konstantinou, M.P.; Gerdes, S.; Rissler, M.; Gathmann, S.; Sieder, C.; Baeumer, D.; Orsenigo, R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 11(2020) Page Start: 2548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Continued treatment with secukinumab is associated with high retention or regain of response. (17th July 2019) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Continued treatment with secukinumab is associated with high retention or regain of response. (1st January 2020) Authors: Augustin, M.; Thaci, D.; Eyerich, K.; Pinter, A.; Radtke, M.; Lauffer, F.; Mrowietz, U.; Gerdes, S.; Pariser, D.; Lebwohl, M.; Sieder, C.; Melzer, N.; Reich, K. Journal: British journal of dermatology Issue: Volume 182:Number 1(2020) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of omalizumab on angioedema in H1‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ACT, a randomized controlled trial. Issue 8 (31st March 2016) Authors: Staubach, P.; Metz, M.; Chapman‐Rothe, N.; Sieder, C.; Bräutigam, M.; Canvin, J.; Maurer, M. Journal: Allergy Issue: Volume 71:Issue 8(2016:Aug.) Page Start: 1135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data. Issue 3 (11th December 2017) Authors: Staubach, P.; Metz, M.; Chapman‐Rothe, N.; Sieder, C.; Bräutigam, M.; Maurer, M.; Weller, K. Journal: Allergy Issue: Volume 73:Issue 3(2018) Page Start: 576 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients. (30th November 2015) Authors: van Koningsbruggen-Rietschel, S.; Heuer, H. E.; Merkel, N.; Posselt, H. G.; Staab, D.; Sieder, C.; Ziegler, J.; Krippner, F.; Rietschel, E. Journal: Journal of antimicrobial chemotherapy Issue: Volume 71:Number 3(2016:Mar.) Page Start: 711 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study*. (1st May 2021) Authors: Reich, K.; Körber, A.; Mrowietz, U.; Sticherling, M.; Sieder, C.; Früh, J.; Bachhuber, T. Journal: British journal of dermatology Issue: Volume 184:Number 5(2021) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study. (18th November 2020) Authors: Reich, K.; Körber, A.; Mrowietz, U.; Sticherling, M.; Sieder, C.; Früh, J.; Bachhuber, T. Journal: British journal of dermatology Issue: Volume 184:Number 5(2021) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study. (1st May 2021) Authors: Reich, K.; Körber, A.; Mrowietz, U.; Sticherling, M.; Sieder, C.; Früh, J.; Bachhuber, T. Journal: British journal of dermatology Issue: Volume 184:Number 5(2021) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study. (1st February 2020) Authors: Reich, K.; Puig, L.; Szepietowski, J.C.; Paul, C.; Lacour, J.P.; Tsianakas, A.; Sieder, C.; Rissler, M.; Pournara, E.; Orsenigo, R. Journal: British journal of dermatology Issue: Volume 182:Number 2(2020) Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗